Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Denali Therapeutics (DNLI) Accumulated Depreciation & Amortization (2017 - 2025)

Denali Therapeutics has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $11.2 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 43.46% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2025, up 43.46% year-over-year, with the annual reading at $11.2 million for FY2025, 43.46% up from the prior year.
  • Accumulated Depreciation & Amortization was $11.2 million for Q4 2025 at Denali Therapeutics, up from $7.8 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $16.7 million in Q4 2023 and troughed at $7.8 million in Q4 2024.
  • The 5-year median for Accumulated Depreciation & Amortization is $10.4 million (2022), against an average of $10.9 million.
  • Year-over-year, Accumulated Depreciation & Amortization skyrocketed 60.83% in 2023 and then crashed 53.4% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $8.6 million in 2021, then rose by 21.03% to $10.4 million in 2022, then skyrocketed by 60.83% to $16.7 million in 2023, then crashed by 53.4% to $7.8 million in 2024, then skyrocketed by 43.46% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Accumulated Depreciation & Amortization are $11.2 million (Q4 2025), $7.8 million (Q4 2024), and $16.7 million (Q4 2023).